Our Blogs

According to Bloomberg.com, the Danish maker of a vaginal mesh implant has agreed to pay about $16 million to settle lawsuits accusing the company of injuring women.Photo of mesh product Denmark-based Coloplast agreed in January

Boehringer Ingelheim, the manufacturer of the blood thinning drug Pradaxa, announced a $650 million settlement deal today to settle around 4,000 state and federal lawsuits. Pradaxa is a widely-used blood thinner, but it has been alleged to

If you take Pradaxa (dabigatran), you should use caution. The drug has been linked to a higher risk for fatal health problems when compared to individuals using the blood thinner Warfarin. In a study of more

The Food and Drug Administration (FDA) has thoroughly reviewed the scientific literature on using transvaginal mesh to treat pelvic organ prolapse (POP) in women. Based on this review, the FDA says it has not seen enough evidence to support

Reuters reported last week that U.S. courts would start to hear cases against Boehringer Ingelheim over its stroke prevention pill Pradaxa (dabigatran) in August. The manufacturer is facing more than 2,000 lawsuits in the U.S. over claims the

Have you suffered pain because of a defective transvaginal mesh implant? Has your sex life been interrupted because an implant has made it difficult to have intercourse? Transvaginal mesh (TVM) implants have been linked to recurrent pelvic

According to WEWS-TV, Pradaxa (dabigatran) is the most complained about drug in the United States. The television station reported that more complaints were filed with the U.S. Food and Drug Administration (FDA) about Pradaxa than any other

Last week, the Pittsburgh Post-Gazette reported that “despite major advances in research, between 30 and 40 percent of all people diagnosed with depression don’t respond to standard treatments.” According to the Post-Gazette, the failure rate for depression treatment is

Several media outlets are reporting that Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for Pradaxa use to treat venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and

According to the Institute for Safe Medication Practices (ISMP), in 2012 the US Food and Drug Administration (FDA) Adverse Event Reporting System received more than 3,200 reports of problems associated with the drug Pradaxa. Pradaxa is